摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetic acid | 1300019-38-8

中文名称
——
中文别名
——
英文名称
[(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetic acid
英文别名
(S)-2-(6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetic acid;2-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetic acid;I-BET762 carboxylic acid;2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetic acid
[(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetic acid化学式
CAS
1300019-38-8
化学式
C20H17ClN4O3
mdl
——
分子量
396.833
InChiKey
VEIZLTSJCDOIBH-INIZCTEOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    648.3±65.0 °C(Predicted)
  • 密度:
    1.44±0.1 g/cm3(Predicted)
  • 溶解度:
    二甲基亚砜:7.14 mg/mL(17.99 mM)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    28
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    89.6
  • 氢给体数:
    1
  • 氢受体数:
    6

安全信息

  • 储存条件:
    -20°C,密闭保存,干燥环境

制备方法与用途

Target Protein-binding Moiety 4 是一个抑制剂,其IC50值为7.9 μM。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    —— methyl [(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetate 1300019-40-2 C21H19ClN4O3 410.86
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    —— ethyl [(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetate 1300746-12-6 C22H21ClN4O3 424.887
    —— butyl 2-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f ][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetate 1300746-14-8 C24H25ClN4O3 452.941
    —— (S)-tert-butyl-2-(6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetate 1300746-30-8 C24H25ClN4O3 452.941
    —— ethyl[(4S)-6-(4-chlorophenyl)-8-hydroxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetate 1352937-96-2 C21H19ClN4O3 410.86
    GSK 525762A; (4S)-6-(4-氯苯基)-N-乙基-8-甲氧基-1-甲基-4H-[1,2,4]三唑并[4,3-a][1,4]苯并二氮杂卓-4-乙酰胺 I-BET762 1260907-17-2 C22H22ClN5O2 423.902
    —— (S)-N-(2-aminoethyl)-2-(6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetamide 1426686-72-7 C22H23ClN6O2 438.917
    —— (S)-2-(8-(2-aminoethoxy)-6-(4-chlorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)-N-ethylacetamide 1426686-92-1 C23H25ClN6O2 452.944
    —— 2-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)-N-(29-hydroxy-3,6,9,12,15,18,21,24,27-nonaoxanonacosyl)acetamide 1426687-13-9 C40H58ClN5O12 836.38
    —— (S)-N,N’-(3,6,9,12-tetraoxatetradecane-1,14-diyl)bis(2-((S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetamide) 1426686-58-9 C50H54Cl2N10O8 993.947
    —— N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetamide —— C26H31ClN6O4 527.023
    • 1
    • 2
    • 3
    • 4

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR LE TRAITEMENT D'UNE MALADIE GÉNÉTIQUE
    申请人:DESIGN THERAPEUTICS INC
    公开号:WO2021158707A1
    公开(公告)日:2021-08-12
    The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
    本公开涉及化合物和方法,用于调节dmpk的表达,并治疗dmpk发挥积极作用的疾病和病况。该化合物可以是一种转录调节分子,具有第一末端、第二末端和寡聚骨架,其中:a)第一末端包括一种DNA结合基团,能够非共价结合到核苷酸重复序列CAG或CTG;b)第二末端包括结合到调节分子的蛋白结合基团,该调节分子调节包含核苷酸重复序列CAG或CTG的基因的表达;c)寡聚骨架包括连接第一末端和第二末端的连接物。
  • [EN] TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE<br/>[FR] DÉRIVÉS DE TÉTRAHYDROQUINOLINE ET LEUR UTILISATION PHARMACEUTIQUE
    申请人:GLAXOSMITHKLINE LLC
    公开号:WO2011054841A1
    公开(公告)日:2011-05-12
    Tetrahydroquinoline compounds of Formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
    Formula (I)的四氢喹啉化合物及其盐,含有这种化合物的药物组合物以及它们在治疗中的用途。
  • Condensed Azepine Derivatives As Bromodomain Inhibitors
    申请人:Crowe Miriam
    公开号:US20120202799A1
    公开(公告)日:2012-08-09
    Benzodiazepine compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
    苯二氮卓类化合物的化学式(I)及其盐,含有这类化合物的药物组合物以及它们在治疗中的应用。
  • Tetrahydroquinoline Derivatives And Their Pharmaceutical Use
    申请人:Demont Emmanuel Hubert
    公开号:US20120208798A1
    公开(公告)日:2012-08-16
    Tetrahydroquinoline compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
    公式(I)的四氢喹啉化合物及其盐,含有这种化合物的药物组合物以及它们在治疗中的用途。
  • [EN] CONDENSED AZEPINE DERIVATIVES AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS CONDENSÉS D'AZÉPINES CONVENANT COMME INHIBITEURS DU BROMODOMAINE
    申请人:GLAXOSMITHKLINE LLC
    公开号:WO2011054844A1
    公开(公告)日:2011-05-12
    Benzodiazepine compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
    苯二氮卓类化合物的化学式(I)及其盐,含有这类化合物的药物组合物以及它们在治疗中的应用。
查看更多